Low retention of [S-methyl-11C]MeS-IMPY to β-amyloid plaques in patients with Alzheimer's disease

Nicholas Seneca, Lisheng Cai, Jeih San Liow, Sami S. Zoghbi, Robert Gladding, John T. Little, Paul S. Aisen, Jinsoo Hong, Victor W. Pike, Robert B. Innis

Research output: Contribution to journalArticle

Abstract

Alzheimer's disease (AD) is characterized pathologically by the accumulation of β-amyloid plaques in brain. We developed a novel positron emission tomographic (PET) radioligand, [11C]MeS-IMPY ([S-methyl-11C]N,N-dimethyl- 4-(6-(methylthio)imidazo[1,2-a]pyridine-2-yl)aniline). The objective of this study was to determine if [11C]MeS-IMPY can detect β-amyloid plaques in patients with AD. Ten subjects (4 patients with AD and 6 healthy controls) had PET scans of 90 min as well as serial sampling of arterial plasma. Total distribution volume was calculated from radioactivity in brain and concentrations of radioligand in arterial plasma. After injection of [11C]MeS-IMPY in both groups, peak brain uptake was high (~ 450% SUV), peaked early at ~ 2 min and washed out quickly. The time-course of brain radioactivity in all regions was virtually identical in AD patients and healthy controls. Although distribution volume of neocortical re- gions was ~ 26% higher in AD patients than in controls, the differences were statistically insignificant (P = 0.143). In ad- dition, distribution volume in all regions and in both groups increased during the entire scan, which is consistent with the accumulation of radiometabolite(s) in brain. The rapid washout of [11C]MeS-IMPY from brain may have been caused by inadequate binding affinity, and the small differences between patients and healthy subjects were likely caused, in part, by the accumulation of radiometabolite(s) in brain. We conclude that [11C]MeS-IMPY is able to image β-amyloid in brains of patients with AD, but that chemical analogs with higher affinity and non-problematic radiometabolites will be more useful imaging agents.

Original languageEnglish (US)
Pages (from-to)129-136
Number of pages8
JournalCurrent Radiopharmaceuticals
Volume2
Issue number2
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Amyloid Plaques
Alzheimer Disease
Brain
Radioactivity
Electrons
N,N-dimethyl-4-(6-(methylthio)imidazo(1,2-a)pyridine-2-yl)aniline
Amyloid
Healthy Volunteers
Injections

Keywords

  • β-amyloid
  • [C]MeS-IMPY
  • Alzheimer's disease
  • Positron emission tomography

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Pharmacology

Cite this

Seneca, N., Cai, L., Liow, J. S., Zoghbi, S. S., Gladding, R., Little, J. T., ... Innis, R. B. (2009). Low retention of [S-methyl-11C]MeS-IMPY to β-amyloid plaques in patients with Alzheimer's disease. Current Radiopharmaceuticals, 2(2), 129-136. https://doi.org/10.2174/1874471010902020129

Low retention of [S-methyl-11C]MeS-IMPY to β-amyloid plaques in patients with Alzheimer's disease. / Seneca, Nicholas; Cai, Lisheng; Liow, Jeih San; Zoghbi, Sami S.; Gladding, Robert; Little, John T.; Aisen, Paul S.; Hong, Jinsoo; Pike, Victor W.; Innis, Robert B.

In: Current Radiopharmaceuticals, Vol. 2, No. 2, 2009, p. 129-136.

Research output: Contribution to journalArticle

Seneca, N, Cai, L, Liow, JS, Zoghbi, SS, Gladding, R, Little, JT, Aisen, PS, Hong, J, Pike, VW & Innis, RB 2009, 'Low retention of [S-methyl-11C]MeS-IMPY to β-amyloid plaques in patients with Alzheimer's disease', Current Radiopharmaceuticals, vol. 2, no. 2, pp. 129-136. https://doi.org/10.2174/1874471010902020129
Seneca, Nicholas ; Cai, Lisheng ; Liow, Jeih San ; Zoghbi, Sami S. ; Gladding, Robert ; Little, John T. ; Aisen, Paul S. ; Hong, Jinsoo ; Pike, Victor W. ; Innis, Robert B. / Low retention of [S-methyl-11C]MeS-IMPY to β-amyloid plaques in patients with Alzheimer's disease. In: Current Radiopharmaceuticals. 2009 ; Vol. 2, No. 2. pp. 129-136.
@article{c603f15933704e6fa37ffb40081daaac,
title = "Low retention of [S-methyl-11C]MeS-IMPY to β-amyloid plaques in patients with Alzheimer's disease",
abstract = "Alzheimer's disease (AD) is characterized pathologically by the accumulation of β-amyloid plaques in brain. We developed a novel positron emission tomographic (PET) radioligand, [11C]MeS-IMPY ([S-methyl-11C]N,N-dimethyl- 4-(6-(methylthio)imidazo[1,2-a]pyridine-2-yl)aniline). The objective of this study was to determine if [11C]MeS-IMPY can detect β-amyloid plaques in patients with AD. Ten subjects (4 patients with AD and 6 healthy controls) had PET scans of 90 min as well as serial sampling of arterial plasma. Total distribution volume was calculated from radioactivity in brain and concentrations of radioligand in arterial plasma. After injection of [11C]MeS-IMPY in both groups, peak brain uptake was high (~ 450{\%} SUV), peaked early at ~ 2 min and washed out quickly. The time-course of brain radioactivity in all regions was virtually identical in AD patients and healthy controls. Although distribution volume of neocortical re- gions was ~ 26{\%} higher in AD patients than in controls, the differences were statistically insignificant (P = 0.143). In ad- dition, distribution volume in all regions and in both groups increased during the entire scan, which is consistent with the accumulation of radiometabolite(s) in brain. The rapid washout of [11C]MeS-IMPY from brain may have been caused by inadequate binding affinity, and the small differences between patients and healthy subjects were likely caused, in part, by the accumulation of radiometabolite(s) in brain. We conclude that [11C]MeS-IMPY is able to image β-amyloid in brains of patients with AD, but that chemical analogs with higher affinity and non-problematic radiometabolites will be more useful imaging agents.",
keywords = "β-amyloid, [C]MeS-IMPY, Alzheimer's disease, Positron emission tomography",
author = "Nicholas Seneca and Lisheng Cai and Liow, {Jeih San} and Zoghbi, {Sami S.} and Robert Gladding and Little, {John T.} and Aisen, {Paul S.} and Jinsoo Hong and Pike, {Victor W.} and Innis, {Robert B.}",
year = "2009",
doi = "10.2174/1874471010902020129",
language = "English (US)",
volume = "2",
pages = "129--136",
journal = "Current Radiopharmaceuticals",
issn = "1874-4710",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Low retention of [S-methyl-11C]MeS-IMPY to β-amyloid plaques in patients with Alzheimer's disease

AU - Seneca, Nicholas

AU - Cai, Lisheng

AU - Liow, Jeih San

AU - Zoghbi, Sami S.

AU - Gladding, Robert

AU - Little, John T.

AU - Aisen, Paul S.

AU - Hong, Jinsoo

AU - Pike, Victor W.

AU - Innis, Robert B.

PY - 2009

Y1 - 2009

N2 - Alzheimer's disease (AD) is characterized pathologically by the accumulation of β-amyloid plaques in brain. We developed a novel positron emission tomographic (PET) radioligand, [11C]MeS-IMPY ([S-methyl-11C]N,N-dimethyl- 4-(6-(methylthio)imidazo[1,2-a]pyridine-2-yl)aniline). The objective of this study was to determine if [11C]MeS-IMPY can detect β-amyloid plaques in patients with AD. Ten subjects (4 patients with AD and 6 healthy controls) had PET scans of 90 min as well as serial sampling of arterial plasma. Total distribution volume was calculated from radioactivity in brain and concentrations of radioligand in arterial plasma. After injection of [11C]MeS-IMPY in both groups, peak brain uptake was high (~ 450% SUV), peaked early at ~ 2 min and washed out quickly. The time-course of brain radioactivity in all regions was virtually identical in AD patients and healthy controls. Although distribution volume of neocortical re- gions was ~ 26% higher in AD patients than in controls, the differences were statistically insignificant (P = 0.143). In ad- dition, distribution volume in all regions and in both groups increased during the entire scan, which is consistent with the accumulation of radiometabolite(s) in brain. The rapid washout of [11C]MeS-IMPY from brain may have been caused by inadequate binding affinity, and the small differences between patients and healthy subjects were likely caused, in part, by the accumulation of radiometabolite(s) in brain. We conclude that [11C]MeS-IMPY is able to image β-amyloid in brains of patients with AD, but that chemical analogs with higher affinity and non-problematic radiometabolites will be more useful imaging agents.

AB - Alzheimer's disease (AD) is characterized pathologically by the accumulation of β-amyloid plaques in brain. We developed a novel positron emission tomographic (PET) radioligand, [11C]MeS-IMPY ([S-methyl-11C]N,N-dimethyl- 4-(6-(methylthio)imidazo[1,2-a]pyridine-2-yl)aniline). The objective of this study was to determine if [11C]MeS-IMPY can detect β-amyloid plaques in patients with AD. Ten subjects (4 patients with AD and 6 healthy controls) had PET scans of 90 min as well as serial sampling of arterial plasma. Total distribution volume was calculated from radioactivity in brain and concentrations of radioligand in arterial plasma. After injection of [11C]MeS-IMPY in both groups, peak brain uptake was high (~ 450% SUV), peaked early at ~ 2 min and washed out quickly. The time-course of brain radioactivity in all regions was virtually identical in AD patients and healthy controls. Although distribution volume of neocortical re- gions was ~ 26% higher in AD patients than in controls, the differences were statistically insignificant (P = 0.143). In ad- dition, distribution volume in all regions and in both groups increased during the entire scan, which is consistent with the accumulation of radiometabolite(s) in brain. The rapid washout of [11C]MeS-IMPY from brain may have been caused by inadequate binding affinity, and the small differences between patients and healthy subjects were likely caused, in part, by the accumulation of radiometabolite(s) in brain. We conclude that [11C]MeS-IMPY is able to image β-amyloid in brains of patients with AD, but that chemical analogs with higher affinity and non-problematic radiometabolites will be more useful imaging agents.

KW - β-amyloid

KW - [C]MeS-IMPY

KW - Alzheimer's disease

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=77953760524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953760524&partnerID=8YFLogxK

U2 - 10.2174/1874471010902020129

DO - 10.2174/1874471010902020129

M3 - Article

VL - 2

SP - 129

EP - 136

JO - Current Radiopharmaceuticals

JF - Current Radiopharmaceuticals

SN - 1874-4710

IS - 2

ER -